Search

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

11.14 4.8

Resumen

Variación precio

24h

Actual

Mínimo

10.36

Máximo

11.15

Métricas clave

By Trading Economics

Ingresos

978K

Ventas

135M

P/B

Media del Sector

4.272

62.58

Margen de beneficios

0.722

Empleados

1,796

EBITDA

-14M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+33.72% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.9B

Apertura anterior

6.34

Cierre anterior

11.14

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

324 / 340 Clasificación en Healthcare

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 jul 2026, 23:56 UTC

Correlated Moves
News

Diamondback Energy gained during after-market hours, buoyed by strong revenue growth and a favorable market position, with shares peaking above Monday's close.

27 jul 2026, 23:51 UTC

News
Event

UDR Inc reported second-quarter net income of $69.035 million. Shares declined in after-market trading amid concerns over flat revenue and rising costs.

27 jul 2026, 23:51 UTC

News

L3Harris Technologies has secured Pentagon agreements to boost missile defense production, but shares are trading lower in after-market hours.

27 jul 2026, 23:51 UTC

News
Social Media

Tesla Inc shares declined in after-market trading, continuing a trend of lower closes over the past four sessions amid analyst caution following its Q2 performance.

27 jul 2026, 23:51 UTC

News

Rivian shares rise in after-market trading as analysts upgrade outlook and boost price target ahead of earnings report on July 30.

27 jul 2026, 23:51 UTC

News

Cincinnati Financial Corp shares fell in after-market hours following second-quarter results that missed expectations for EPS and revenue. Earlier in the session, shares briefly rose.

27 jul 2026, 23:51 UTC

News
Social Media

Cadence Design Systems shares are higher in after-market trading following strong Q2 results and an increase in full-year revenue guidance to $6.26 billion to $6.34 billion.

27 jul 2026, 23:51 UTC

News
Social Media

Microstrategy shares declined in after-market hours following Peter Schiff's criticism of the company's Bitcoin yield, which fell significantly in recent months.

27 jul 2026, 23:51 UTC

News

Accenture PLC shares are lower in after-market hours despite a $2 billion share repurchase program and a quarterly dividend announcement.

27 jul 2026, 23:51 UTC

News

NIO shares rose in after-market trading, building on regular-session gains. Options activity showed bullish sentiment, with calls outpacing puts significantly.

27 jul 2026, 23:51 UTC

News
Social Media
Correlated Moves

Micron Technology Inc shares declined in after-market trading following a report raising concerns about the company's growth potential and future demand for memory chips.

27 jul 2026, 23:51 UTC

News
Social Media

Amkor Technology's shares declined in after-market trading following weaker-than-expected third-quarter revenue guidance despite strong second-quarter results and earnings.

27 jul 2026, 23:42 UTC

News
Correlated Moves

Bitcoin is trading lower as easing geopolitical tensions reduce demand for safe-haven assets. Ethereum also declines, reflecting its correlation with Bitcoin's market movements.

27 jul 2026, 23:42 UTC

Correlated Moves
News

Bitcoin is trading lower as easing geopolitical tensions reduce demand for safe-haven assets. Ethereum also declines amid similar market dynamics.

27 jul 2026, 23:41 UTC

News
Correlated Moves

NBT Bancorp shares are higher in after-market trading following second-quarter results, which included net income of $53 million and a dividend increase to $0.40 per share.

27 jul 2026, 23:41 UTC

News
Social Media

Brown & Brown Inc reported second-quarter revenues of $1.68 billion, missing expectations. Shares are trading lower in after-market hours following the mixed results.

27 jul 2026, 23:41 UTC

News

OPKO Health reported second-quarter revenues of $163.5 million, surpassing expectations. The company also raised its full-year sales guidance, boosting shares in after-market trading.

27 jul 2026, 23:41 UTC

News

International Paper shares are higher in after-market trading as CEO Andy Silvernail prepares to present at the Jefferies 2026 Industrials Conference on September 10.

27 jul 2026, 23:41 UTC

News

Oil prices are higher in after-market hours, supported by reduced supply disruption concerns from the Middle East and gains in European markets.

27 jul 2026, 23:31 UTC

News

Northwest Bancshares reported second-quarter adjusted EPS of $0.37 and revenue of $181.2 million, exceeding expectations. Shares are trading higher in after-market hours.

27 jul 2026, 23:31 UTC

News
Social Media

Johnson & Johnson shares are higher in after-market trading following a proposed $5.5 billion settlement for ovarian talc litigation involving about 76,000 claims.

27 jul 2026, 23:31 UTC

News
Social Media

ServiceNow shares rose during after-market hours as software stocks recovered. CEO Bill McDermott reported no slowdown in demand amid mixed social media sentiment on AI impacts.

27 jul 2026, 23:26 UTC

News

Nucor Corporation reported second-quarter earnings of $1.16 billion, exceeding estimates. Shares are trading higher in after-market hours following the strong results.

27 jul 2026, 23:16 UTC

News
Social Media

Intel Corp shares are lower in after-market hours following a $2.1 billion loss, despite a 25% revenue increase to $16.1 billion in Q2.

27 jul 2026, 23:16 UTC

News

Dell Technologies Inc. shares are lower in after-market hours, continuing a trend from the previous three sessions amid a focus on AI-optimized infrastructure solutions.

27 jul 2026, 23:16 UTC

News

Zoetis shares are lower in after-market hours following a class action lawsuit alleging securities fraud and reduced profit guidance to between $6.85 and $7.00 per share.

27 jul 2026, 23:11 UTC

News

Albertsons Companies Inc shares are lower in after-market hours amid an investigation into potential securities law violations and a Q1 EPS miss of $0.42.

27 jul 2026, 23:02 UTC

News
Social Media

Welltower reported strong Q2 results, raising full-year FFO guidance and increasing its dividend. Shares are trading higher in after-market hours.

27 jul 2026, 23:02 UTC

News
Social Media

Sanmina Corp shares are lower in after-market trading despite strong Q3 results, as Q4 guidance fell short of consensus estimates.

27 jul 2026, 23:02 UTC

News

GoPro Inc. will release its Q2 financial results on August 10, 2026, contributing to a higher after-market price as investors anticipate insights.

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

33.72% repunte

Estimación a 12 Meses

Media 14.87 USD  33.72%

Máximo 17 USD

Mínimo 13.6 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

1

Comprar

2

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat